Journey Medical Corporation (Nasdaq:DERM), a pharmaceutical company with a focus on dermatological conditions, on Monday announced the launch and initial distribution of Emrosi, a 40 mg modified-release minocycline hydrochloride capsule, for the treatment of inflammatory lesions of rosacea in adults.
The product is available through specialty pharmacy chains.
Approved by the US Food and Drug Administration in November 2024, Emrosi is the lowest-dose oral minocycline available for rosacea treatment. Clinical trials demonstrated that Emrosi provides superior clinical outcomes compared to Oracea and placebo, while maintaining a comparable safety profile.
The first prescriptions of Emrosi have been filled.
Claude Maraoui, CEO of Journey Medical, said that the launch of Emrosi represents a major milestone for the company and reinforces its commitment to improving the quality of life for individuals with dermatological conditions.
Intelligent Bio Solutions strengthens IP with sixth US patent ahead of 2025 market entry
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
Nyxoah receives FDA Approvable Letter for Genio system
Palatin Technologies' PL7737 granted US FDA orphan drug designation
Benuvia Operations receives five-year contract from NIDA
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Sanofi's tolebrutinib receives FDA priority review for multiple sclerosis treatment
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Agilent xCELLigence technology Supports FDA Approval of AUCATZYL
Journey Medical launches Emrosi for treatment of rosacea
Everest Medicines' EVM14 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab